BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 15, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Regulatory actions for Oct. 28, 2022

Oct. 28, 2022
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Avrobio, Diamedica, Dyadic International, ITM Isotope Technologies München, Myeloid, Novo Nordisk, Reveragen, Santhera, Simcere.
Read More
Infection

Pfizer discloses new 3CLpro viral inhibitors for COVID-19 treatment

Oct. 28, 2022
Pfizer Inc. has divulged 3C-like proteinase (3CLpro) (SARS-CoV-2) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Read More

Regulatory actions for Oct. 27, 2022

Oct. 27, 2022
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Novacyt, Radiaction, Transit Scientific.
Read More

Other news to note for Oct. 27, 2022

Oct. 27, 2022
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 2seventy, Aquestive, Assertio, BMS, Ignyte, JW, Kissei, Obseva, Obsidian, Peak, Res Nova, Soligenix and Therapeutic Solutions.
Read More

In the clinic for Oct. 27, 2022

Oct. 27, 2022
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Acelrx, Aileron, Anixa, Astrazeneca, Atara, Biogen, BMS, Boehringer, Cocrystal, Codagenix, Corvus, Covis, Effector, Essa, Exelixis, Foghorn, Hepion, Horizon, Immutep, Jaguar, Kura, Merck, Merus, Morphic, Nurix, Olema, Oncopeptides, Redhill, Ryvu, Viiv.
Read More

Other news to note for Oct. 26, 2022

Oct. 26, 2022
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Biohaven and Candel.
Read More

In the clinic for Oct. 26, 2022

Oct. 26, 2022
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Applied, Astrazeneca, Atai, Avrobio, Can-Fite, Cardiol, Gristone, Imaginab, Inotrem, Oblato, Quadriga, Seelos and Ultimovacs.
Read More
IV drip

Inotrem’s nangibotide shines in curtailed COVID-19 trial

Oct. 25, 2022
By Cormac Sheridan
Inotrem SA obtained an unexpectedly robust efficacy signal from a curtailed phase II trial of nangibotide, an inhibitor of triggering receptor expressed on myeloid cells 1, in patients with severe COVID-19.
Read More

Positive phase III clinical trial data for Sinocelltech’s COVID-19 vaccines

Oct. 25, 2022
By Zhang Mengying
Sinocelltech Group Ltd. has reported positive interim data for two COVID-19 vaccine candidates, SCTV-01C and SCTV-01E, from phase III trials in the United Arab Emirates.
Read More

Regulatory actions for Oct. 25, 2022

Oct. 25, 2022
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Acumen, Astrazeneca, Daiichi, JJP, Leo, Merck & Co., Novaliq, Novavax, Sensorion, Vanda, Vaxxinity.
Read More
Previous 1 2 … 70 71 72 73 74 75 76 77 78 … 552 553 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 12, 2026.
  • Neck exam

    Ethyreal launches to treat the underlying cause of Graves’, TED

    BioWorld
    Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
  • Purple molecules

    Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis

    BioWorld
    Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
  • 3D illustration of a nerve cell

    Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?

    BioWorld
    Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
  • Illustration of Lactobacillus

    Microbiota modulates the antidepressant effects of GLP-1 analogues

    BioWorld Science
    Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing